{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "earningsTimestamp": 1678969800, "earningsTimestampStart": 1686567540, "earningsTimestampEnd": 1686916800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.27, "sharesOutstanding": 82265296, "bookValue": -0.287, "fiftyDayAverage": 0.362169, "fiftyDayAverageChange": -0.00066900253, "fiftyDayAverageChangePercent": -0.0018472109, "twoHundredDayAverage": 0.3791936, "twoHundredDayAverageChange": -0.017693609, "twoHundredDayAverageChangePercent": -0.04666115, "marketCap": 29738904, "priceToBook": -1.2595818, "currency": "USD", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.3615, "firstTradeDateMilliseconds": 1600867800000, "priceHint": 4, "exchange": "PNK", "shortName": "VALEO PHARMA INC", "longName": "Valeo Pharma Inc.", "messageBoardId": "finmb_36312531", "regularMarketChange": 0.0, "regularMarketTime": 1683908133, "regularMarketDayHigh": 0.3615, "regularMarketDayRange": "0.3615 - 0.3615", "regularMarketDayLow": 0.3615, "regularMarketVolume": 1445, "regularMarketPreviousClose": 0.3615, "fullExchangeName": "Other OTC", "financialCurrency": "CAD", "regularMarketOpen": 0.3615, "averageDailyVolume3Month": 1746, "averageDailyVolume10Day": 1363, "fiftyTwoWeekLowChange": 0.1339, "fiftyTwoWeekLowChangePercent": 0.58831286, "fiftyTwoWeekRange": "0.2276 - 0.6589", "fiftyTwoWeekHighChange": -0.29740003, "fiftyTwoWeekHighChangePercent": -0.45135835, "fiftyTwoWeekLow": 0.2276, "fiftyTwoWeekHigh": 0.6589, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "displayName": "Valeo Pharma", "symbol": "VPHIF"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "16667 Hymus Boulevard", "city": "Kirkland", "state": "QC", "zip": "H9H 4R9", "country": "Canada", "phone": "514-694-0150", "fax": "514-694-0865", "website": "https://www.valeopharma.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. It also offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. In addition, the company provides Ametop Gel 4%, for skin anesthesia prior to injection or cannulation; Sabizabulin, oral dual antiviral/anti-inflammatory agent for high-risk hospitalized adults suffering from covid-19; Simbrinza, ophthalmic drops to treat openangle glaucoma or ocular hypertension; Xiidra, an prescription based eye-drop to treat dry eye disease; and Allerject, a portable voice-activated epinephrine injector for emergency treatment of serious allergic reactions. Its primary therapeutic areas include respiratory / allergy, ophthalmology, and specialty and hospital generic products. Valeo Pharma Inc. was incorporated in 2003 and is headquartered in Kirkland, Canada.", "fullTimeEmployees": 120, "companyOfficers": [{"maxAge": 1, "name": "Mr. Steven  Saviuk CA", "age": 63, "title": "Vice Chairman, Pres & CEO", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 176813, "fmt": "176.81k", "longFmt": "176,813"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Luc  Mainville M.B.A, M.B.A.", "age": 58, "title": "Sr. VP & CFO", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": {"raw": 135431, "fmt": "135.43k", "longFmt": "135,431"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Frederic  Dumais", "title": "Director of Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Guy-Paul  Allard", "title": "VP of Legal Affairs & Corp. Sec.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kyle  Steiger", "title": "Sr. VP & Chief Commercial Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jean Francois Fournier", "title": "Head of Ophthalmology Bus. Unit", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}